Dechra Pharmaceuticals plc (LON:DPH) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,784 ($24.01).

Separately, Jefferies Group raised their price target on Dechra Pharmaceuticals from GBX 1,565 ($21.06) to GBX 1,868 ($25.14) and gave the stock a “hold” rating in a report on Tuesday, September 5th.

In related news, insider Ian Page sold 54,910 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($27.24), for a total value of £1,111,378.40 ($1,495,798.65).

Shares of Dechra Pharmaceuticals (LON DPH) traded up GBX 13.20 ($0.18) on Thursday, hitting GBX 2,054.20 ($27.65). 66,637 shares of the stock were exchanged, compared to its average volume of 127,121. Dechra Pharmaceuticals has a 1 year low of GBX 1,225 ($16.49) and a 1 year high of GBX 2,272 ($30.58).

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at

About Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with's FREE daily email newsletter.